|
South Korea Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The South Korea Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for South Korea .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Korean pharmaceutical and healthcare industry.
Competitive intelligence, Korean pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Korean market.
The South Korea Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s South Korea Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Korean pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on South Korea to test other views – a key input for successful budgeting and strategic business planning in the Korean pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Korean Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Korea .
- Exploit The Latest Competitive Korean Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in South Korea .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
South Korea Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| South Korea Pharmaceuticals Industry SWOT |
| South Korea Political SWOT |
| South Korea Economic SWOT |
| South Korea Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits Of Potential Returns |
Chapter - South Korea – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Direct-To-Consumer Advertising |
| Intellectual Property Regime |
| Recent Intellectual Property Developments |
| Market Access Barriers |
| Pricing Regime |
| Price Cuts |
| Reimbursement Regime |
| Table: Top 10 Products By Reimbursement Amount, H107 |
| Recent Reimbursement Developments |
| Hospital Purchasing |
| Foreign Trade Developments |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Healthcare System |
| Healthcare System Reforms |
| National Health Insurance Corporation |
| Table: South Korea's National Health Insurance Financial Data (KRWbn) |
| Domestic Pharmaceutical Industry |
| Recent Domestic Industry Developments |
| Foreign Companies |
| Recent Foreign Sector Developments |
| Research And Development |
| Table: New Molecular Entities Developed By South Korean Drugmakers |
| Clinical Trials |
| Biotechnology Sector |
| Table: South Korea's Bio-Industry Backbone |
| Recent Biotechnology Sector Developments |
| Medical Devices |
| Table: Classification Of Medical Devices In South Korea |
| Recent Medical Devices Developments |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: South Korea – Drug Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Industry |
| Table: South Korea – Health Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: South Korea – Economic Activity |
| Prescription Market Forecast |
| Table: South Korea – Prescription Market Indicators, Historical Data And Forecasts (KRWmn unless otherwise stated) |
| Patented Market Forecast |
| Table: South Korea – Patented Market Indicators, Historical Data And Forecasts |
| Generics Market Forecast |
| Table: South Korea – Generics Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| OTC Market Forecast |
| Table: South Korea – OTC Market Indicators, Historical Data And Forecasts (KRWmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: South Korea – Pharmaceutical Trade Indicators, Historical Data And Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: South Korea – Other Healthcare Data Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Multinationals |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Sanofi-Aventis |
| Merck & Co |
| Novartis |
| Eli Lilly |
| Leading Domestic Manufacturers |
| Dong-A |
| Chong Kun Dang Pharmaceutical (CKD) |
| Hanmi Pharmaceutical Co |
| Yuhan Corporation |
| Daewoong Pharmaceutical |
| Bukwang Pharmaceutical |
| Kuhnil Pharmaceutical |
| Choongwae |
Chapter - Country Snapshot: South Korea Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
South Korea Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Business Environment Rankings table for Q209, South Korea moved up by one spot, out of 15 markets assessed in the Asia region, and is now second only to Japan. The country is also regarded as one of the most attractive global (being ranked joint ninth, alongside Canada) pharmaceutical markets due to high per capita consumption and strong annual growth of its already sizeable value. However, while the country’s prospects are considerable, price cuts, limitations on reimbursement and generic substitution will conspire to decelerate the rate of growth over the coming years, exposing South Korea’s stable position to strong competition from nascent pharmaceutical markets in the region.
The 2008 value of South Korea’s pharmaceutical market was estimated at just under US$10bn at consumer prices. The market is forecast to post a compound annual growth rate (CAGR) of 7.65% in local currency terms through to 2013, with the value reaching some US$15.5bn. Key drivers of growth include population ageing and the demand for the chronic and long-term disease treatments, as well as the expected liberalisation of the over-the-counter (OTC) medicine sales. Additionally, while we cut our 2009 real GDP growth forecast from 3.0% to 1.5% on the back of a sharper-than-anticipated slowdown in exports amid government efforts to resuscitate moribund domestic demand, the South Korean economy is likely to be back on its feet in as early as H209.
Nevertheless, the government will continue to work at containing rising healthcare and pharmaceutical costs. To this end, in December 2008, the authorities reduced the listing timeframe for generics and incrementally modified drugs (IMDs, also known as ‘me-too’ products), in accordance with the Drugs Listing Simplification policy. The alterations aim to reduce the time to market for cheaper drugs as well as to encourage generic substitution, with BMI forecasting the share of the generics drugs as a percentage of the total market to increase from 34% in 2008 to 35% in 2013. While faster growth is likely to be prevented by the downward pressure on prices, generics are expected to significantly increase their volume share, as a number of key patents expire. Most recently, domestic drugmakers Kwangdong and Shinpoong announced that they are aiming at capturing 10% market share of the breast cancer market for their generic version of Femara (lestrozole). Nevertheless, in 2008, Sanofi-Aventis’s blood-thinner Plavix (clopidogrel) remained the best-selling drug in South Korea for the third year running, despite recording a negative sales growth in H108.
In the meantime, the merger of three South Korean biotechnology associations – namely Bioindustry Association of Korea (BAK), Korea Bio Venture Association (KOBIOVEN) and Korea Biotechnology Research Association (KBRA) – was finalised in February 2009, further boosting the country’s already sizeable biotechnology sector. The new entity – the Korea Bio Industry Organization (KoreaBIO) – will aim to advance biotechnology research and improve communication between the industry and the government, as well as seek to avoid duplicating effort and resources.
|
South Korea Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |